Svetlana Mojsov

Svetlana Mojsov is a Yugoslav-born Macedonian American chemist who is a Lulu Chow Wang and Robin Chemers Neustein Research Professor at the Rockefeller University. Her research considers peptide synthesis. She discovered the glucagon-like peptide-1 (GLP-1) and uncovered its role in glucose metabolism and the secretion of insulin. Her breakthroughs were transformed by Novo Nordisk into therapeutic agents against diabetes and obesity.

Early life and education Mojsov was born in Skopje, SR Macedonia, SFR Yugoslavia, and did her undergraduate degree in physical chemistry in Belgrade. She joined the graduate program at the Rockefeller University in 1972, where she worked alongside Robert Bruce Merrifield (1984 Nobel Prize in Chemistry) on the synthesis of peptides. Specifically, Mojsov focused on the synthesis of glucagon, a hormone which is released by the pancreas. At the time it was proposed that glucagon might help to treat Type 2 diabetes.

Research and career In the 1980s, Mojsov moved to the Massachusetts General Hospital (MGH) where she was made head of a peptide synthesis facility. She arrived at MGH shortly after Joel Habener had cloned proglucagon by studying anglerfish found in Boston Harbor. Mojsov worked on the identification of glucagon-like peptide-1 (GLP-1), a hormone generated by the gut that triggers the release of insulin. The amino acid sequence of GLP-1 was similar to a gastric inhibitory peptide, an incretin. To try to identify whether a specific fragment of GLP-1 was an incretin, Mojsov synthesized an incretin-antibody and developed ways to track its presence. Specifically, Mojsov identified that a stretch of 31 amino acids in the GLP-1 was an incretin. Together with Gordon Weir at the Joslin Diabetes Center in Boston and Habener, Mojsov showed that small quantities of lab-synthesized GLP-1 could trigger insulin.

In the 1990s, Mojsov returned to New York City, where she went back to Rockefeller University and the laboratory of Ralph M. Steinman (2011 Nobel Prize in Physiology or Medicine). In 1992, the group at Massachusetts General Hospital (MGH) using GLP-1 synthesized by Mojsov tested the GLP-1 in humans. Drugs that emulate the action of GLP-1 have been developed into treatments for obesity and diabetes by Novo Nordisk and Eli Lilly. Eventually, the GLP-1 derivatives Mojsov synthesized, without her knowledge were patented as peptides able to prompt the release of insulin, but with Joel Habener as the sole-creator. She has continued to speak up for credit after her collaborators received various awards as new versions of GLP-1 have been approved and grown popular.

Prizes and awards 2023: VinFuture, Innovators with Outstanding Achievements in Emerging Fields – Jens Juul Holst, Joel Francis Habener, Daniel Joshua Drucker and Svetlana Mojsov 2023: Nature 10 most influential people who shaped science 2024: Pearl Meister Greengard Prize by the Rockefeller University 2024: Time 100 Most Influential People, Pioneers section 2024: Princess of Asturias Awards, Technical and Scientific Research – Daniel J. Drucker, Jeffrey M. Friedman, Joel F. Habener, Jens Juul Holst and Svetlana Mojsov 2024: Tang Prize, Biopharmaceutical Science – Joel F. Habener, Svetlana Mojsov and Jens Juul Holst 2024: Lasker-DeBakey Clinical Medical Research Award – Joel Habener, Svetlana Mojsov and Lotte Bjerre Knudsen 2024: BBVA Foundation Frontiers of Knowledge Awards - Biology and Biomedicne - Daniel Joshua Drucker, Joel Habener, Jens Juul Holst and Svetlana Mojsov 2025: Breakthrough Prize in Life Sciences - Daniel J. Drucker, Joel Habener, Jens Juul Holst, Lotte Bjerre Knudsen and Svetlana Mojsov; Alberto Ascherio and Stephen L. Hauser; and David R. Liu 2025: Warren Triennial Prize – Joel Habener, Daniel J. Drucker, Jens Holst and Svetlana Mojsov 2025: Member of the National Academy of Sciences (Section 42: Medical Physiology and Metabolism) 2025: Distinguished Medical Science Award by the National Library of Medicine - Joel Habener, Svetlana Mojsov and Lotte Bjerre Knudsen 2025: Carothers Award from the American Chemical Society Delaware Section 2025: Helen Dean King Award of Wistar Institute in Philadelphia 2026: Member of the Macedonian Academy of Sciences and Arts 2026: Kimberly Prize in Biochemistry and Molecular Genetics 2026: Boulder Peptide Foundation Meinehofer Award 2026: King Faisal Prize in Medicine 2026: Broermann Medical Innovation Award - Matthias Tschöp, Svetlana Mojsov and Richard DiMarchi

Selected publications Mojsov, Svetlana; Merrifield, R. B. (1984–12). "An improved synthesis of crystalline mammalian glucagon". European Journal of Biochemistry. 145 (3): 601–605. doi:10.1111/j.1432-1033.1984.tb08599.x. ISSN 0014–2956.

Nathan, David M; Schreiber, Eric; Fogel, Howard; Mojsov, Svetlana; Habener, Joel F (1992-02-01). "Insulinotropic Action of Glucagonlike Peptide-I-(7–37) in Diabetic and Nondiabetic Subjects". Diabetes Care. 15 (2): 270–276. doi:10.2337/diacare.15.2.270. ISSN 0149–5992

Personal life Her father was the politician and diplomat Lazar Mojsov. At graduate school Mojsov met her future husband, Michel C. Nussenzweig.

In popular culture In the third chapter of the book Ozempic, la révolution de l'obésité ̶ L’enquête titled A race for patents and Nobel Prizes devoted to Svetlana Mojsov the author Fabrice Delaye summerizes: “In 1982, the identification in animals of the slimming molecule GLP-1 triggered a fierce competition between Danish and American researchers to find it in humans. The race ended in success—but with one casualty: Svetlana Mojsov, a biochemist of Macedonian origin exiled in New York. She was the first to synthesize the molecule that is effective in the human body.”

The second chapter, The Discovery—A Murky Area, of the book Off the Scales by Aimee Donnellan is devoted to the fundamental contribution of Svetlana Mojsov to the discovery of GLP-1, the unfair treatment by her collaborators at the Massachusetts General Hospital in Boston and her long plight to be recognized and included in the patents.